Introduction
There are only a small number of reports on the synthesis and isolation of transition metal hydrogen-bridging complexes. Usually solvent molecules provide the H + source and few researchers suggest the possibility of the reagent NH4PF6 providing the source of H + . Peacock et al. were amongst the first to isolate and characterise by X-ray crystallographic analysis, cobalt, manganese and chromium hydrogen-bridged structures, [ 3 (LH3 = N N N -tris[(2S)-2-hydroxypropyl]-1,4,7-triazacyclononane) respectively. Some of these compounds have been studied using circular dichroism, magnetic susceptibility and cyclic voltammetry, in order to understand their spin states and oxidation states. 2 respectively. All these compounds have a shortened O···O bond distance, averaging 2.34 Å, indicative of strong hydrogen-bonds. In all cases, the hydrogen atoms could not be located in the crystal structures; however their presence is needed in order to balance the PF6 counterions. Nothing has yet been reported on the possible applications of such compounds, therefore we report here the application of hydrogen-bridged ruthenium complexes as possible anti-cancer agents.
In a search for less toxic and more potent alternatives to cisplatin, organometallic complexes have shown promising activity as anti-cancer agents. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Ruthenium-based complexes are some of the most promising, with reported selective potency in vitro and in vivo. [17] [18] [19] [20] [21] [22] McGowan et al. have synthesised a range of ruthenium metal complexes for their uses as anticancer agents. [23] [24] [25] [26] The work published on ruthenium quinaldamides showed that under inert atmosphere conditions, the filtering over NH4PF6 yielded the ruthenium quinaldamide monomers. 27 The use of dry conditions avoids the hydrolysis of NH4PF6 to NH3 and HPF6. These monomeric complexes show low IC50 values against a range of cell lines and also form adducts with guanine nucleotides. Herein, we present the same synthetic strategy using aerobic conditions and show that the monomers are no longer stable under these conditions and the HPF6 present from the hydrolysis of NH4PF6, stabilises two ruthenium quinaldamide species, [{(p-cym)Ru II X(N,N)}{H + }{(N,N)XRu II (pcym)}][PF6], with incorporation of HPF6. This motif has previously been reported for our ruthenium picolinamide complexes, in which an average O···O bond distance of 2.43 Å was observed. 17 The X-ray crystallographic data was reported, however, chemosensitivity studies were not determined.
Herein, chemosensitivity studies have been carried out against HCT116 (human colon carcinoma), A2780 (human ovarian carcinoma) and A2780cis (cisplatin resistant A2780) cancer cell lines, and against non-cancer ARPE-19 (human retinal epithelium) cells. Studies investigated whether the complexes might induce apoptosis (programmed cell death), a cell death mechanism that is commonly suppressed in cancers. This was measured in the HCT116 cancer cells by loss of mitochondrial membrane potential which is an early marker of apoptosis. Cell images by phase contrast microscopy at various timepoints after compound addition suggested induction of cell death rather than growth arrest. Apoptotic analyses revealed a clear correlation between chemosensitivity and levels of apoptosis, whereby the most active compound induces the highest percentage of apoptosis.
Results and discussion
Using a modification of the previously established literature method by Bennett et al., 28, 29 the ruthenium(II) p-cymene halide complexes were synthesised by dissolving Ru III X3.xH2O (X = Cl or Br) and -terpinene in ethanol, then heating to reflux for 16 hours. The resulting dark red powder was filtered and washed with ice cold ethanol to yield the desired starting ruthenium p-cymene dimer. Upon addition of two equivalents of a substituted quinaldamide in ethanol and filtering over NH4PF4, the reaction mixture formed a pale orange precipitate and yielded complexes 1-6 as analytically pure products (Scheme 1). Single orange-red crystals suitable for X-ray crystallographic analysis were obtained for complexes 1-6. They crystallised in either a triclinic P1 (1-3, 5-6) or monoclinic C2/c (4) space group. All of the angles around the metal centre show the geometry expected for pseudo octahedral compounds which is common for half-sandwich -( Tables Chemosensitivity Studies Chemosensitivity studies were undertaken using the MTT assay and IC50 values were determined against HCT116 (human colon carcinoma), A2780 (human ovarian carcinoma) and A2780cis (cisplatin resistant A2780 cells) cell lines, exposed to each of compounds 1-6 or cisplatin ( Table 3) . Against all three cancer cell lines the Ru-Br complexes were consistently more active than the Ru-Cl analogues. The 4-fluoro compounds 2 and 5 are the least active when compared to the other fluoro compounds, however, changing from Ru-Cl (compound 2, 39.2 ± 0.8 M) to Ru-Br (compound 5, 8.7 ± 0.4 M) there is a > 4-T -difluoro compounds 3 and 6 are the most active, and when comparing Ru-Cl (compound 3, 5.9 ± 0.2 M) and Ru-Br (compound 6, 3.9 ± 0.3 M) there is a 1.5-fold increase in cytotoxicity. They is an increase in cytotoxicity when compared Figure 2 The resistance factor for the compounds as indicated. This is defined as the IC50 in A2780cis divided by IC50 in A2780 cells. An RF of 1 indicates equal potency against both cell lines. An RF > 1 indicates that the A2780cis is more resistant than A2780. An RF < 1 indicates that the A2780cis is more sensitive than the A2780 cells.
to the 2'-fluoro compounds 1 and 4, but to a similar degree in both cancer and non-cancer cells. Most of the compounds were more active against A2780 cells than A2780cis cells, but the level of resistance is much less than for that of cisplatin (Figure 2 and Table S3 , SI). Compound 2 is the least potent but showed similar activity towards A2780 and A2780cis cancer cells, and was more active against all three cancer cell lines when compared to non-cancer ARPE-19 cells. The results show that potency is dependent on position of the fluoro. 3.9 ± 0.3 3.0 ± 0.4 6.5 ± 0.9 2.9 ± 0.2 substituent and increasing the number of electron withdrawing substituents increased the potency by > 6-fold. Figure 3 and Table S3 , SI). However, compound 2 is the least active compound against all cancer cell lines tested.
Selectivity for Cancer Cells

Induction of Cancer Cell Death by Apoptosis
IC50 values determined by chemosensitivity studies using the MTT assay indicates the concentration of drug required for a 50% reduction in cell number. This provides invaluable information about the activity of the drug against the cell line but does not distinguish between effects on cell proliferation and effects on cell survival. The observed activity of these compounds towards the cell lines could be caused by induction of cell growth arrest or the compounds may cause cell death. Cell images under phase contrast microscopy at various timepoints after compound addition suggested induction of cell death as suggested by an increase in the proportion of nonadhered cells rather than growth arrest. Using flow cytometry and staining for loss of mitochondrial membrane potential the percentage of apoptotic cells were quantified following incubation of HCT116 cells with 0 60 µM of compounds 1-6 for 72 hours (Figure 4 and Table S4 , SI).
The 2 -difluoro compounds 3 and 6, which were the most active compounds in the MTT chemosensitivity studies, also induced significant levels of apoptotic cell death against HCT116 cancer cell lines (Figure 4 and Table S5 , SI) in a doseresponsive manner. A 72 hour exposure of HCT116 cells to 20 M of compound 3 resulted in ~76% of cells in early stages of apoptosis and compound 6 which was the most active against the MTT assay showed significant apoptosis, with 84% apoptotic cells. In contrast, compounds 2 and 5 were the least active compounds against the MTT assay and show the least amount of apoptotic cells. Compound 2 is the least active of this series of compounds, and a higher concentration of 60 M of the compound had to be used to induce apoptosis, resulting in only 33% apoptotic cells. Whereas the more active compound 5 induces apoptosis at a concentration of 20 M and gave 35% apoptotic cells. These observations indicate a clear correlation between IC50 value and levels of apoptosis induced. 
Conclusions
We report the successful synthesis of ruthenium hydrogenbridged complexes from the reaction of [p-cymRuX2]2 (X = Cl or Br) with a functionalised quinaldamide ligand. The reaction conditions differ from our previously synthesised ruthenium quinaldamide complexes, as here we utilise aerobic conditions and show the hydrolysis of the NH4PF6 reagent yields the stabilisation of these unusual H + bridged complexes, counterbalanced by a PF6 anion. These compounds have been tested against HCT116, A2780 and A2780cis cancer cells, and results -difluoro compounds 3 (X = Cl) and 6 (X = Br) are the most potent against all cell lines. The di-substituted compounds are more potent than the mono-substituted, showing the number and position of the fluoro group is important to the potency. Across all cell lines, the 4-fluoro compounds 2 and 5 are the least active, with >6-fold decrease in potency observed against HCT116 cancer cells. The most significant results when comparing the different ancillary ligands are that the chloride compounds 1-3 are general less active than the bromide complexes 4-6, with up >4-fold increase in IC50 values observed against HCT116 cells. Induction of cell death by apoptosis was investigated and this showed a clear correlation between IC50 values and levels of apoptosis induced. However, the results also indicate the importance to consider selectivity and ability to overcome drug resistance as well as potency with compound appearing the most promising by these important criteria.
Experimental Materials
All chemicals were supplied by Sigma-Aldrich Chemical Co., Acros Organics, Strem Chemical Co. and BOC gases. Functionalised quinaldamide ligands were prepared by adaptations of literature methods. 33 Deuterated NMR solvents were supplied by Sigma-Aldrich Chemical Co. or Acros Organics.
Analysis
All NMR spectra were recorded on a Bruker DPX 300 or a Bruker DPX 500 spectrometer. Microanalyses were recorded at the University of Leeds Microanalytical Service. Mass Spectra were recorded on a Micromass ZMD spectrometer with electrospray ionisation and photoiodide array analyser at the University of Leeds Mass Spectrometry Service.
X-ray Crystallography
A suitable single crystal was selected and immersed in an inert oil. The crystal was then mounted on a glass capillary or nylon loop and attached to a goniometer head on Nonius KappaCCD area detector diffractometer using graphite monochromated Mo-K radiation ( = 0.71073 Å) and a Bruker X8 Apex diffractometer.. The crystal was cooled and data measured at 148-150K by an Oxford Cryostream low temperature device. 34 The full data sets were recorded and the images processed using DENZO and SCALEPACK programs. 35 Structure solution by direct methods was achieved through the use of SHELXS programs, 36 and the structural model refined by full matrix least squares on F 2 using SHELX97 Unless otherwise stated, hydrogen atoms were placed using idealised geometric positions (with free rotation for methyl groups), allowed to were attached, and refined isotropically. Molecular graphics were plotted using OLEX2 37 and Mercury. 38 Editing of CIFs and construction of tables of bond lengths and angles were achieved using WC 39 and PLATON. 30 
Chemosensitvity Studies
In vitro chemosensitivity tests were performed at the University of Huddersfield, against HCT116 (human colon carcinoma), A2780 (human ovarian carcinoma) and A2780cis (cisplatin resistant A2780 cells) cancer cell lines, and against ARPE-19 (human retinal epithelial non-cancer) cells. ARPE-19 cells were obtained from the American Type Culture Collection. Cancer cell lines were routinely maintained as monolayer cultures in appropriate medium (RPMI 1640 supplemented with 10% foetal calf serum, sodium pyruvate (1 mM) and L-glutamine (2 mM) ARPE-19 cells were cultured in DMEM-F12 medium containing 10% foetal calf serum. For chemosensitivity studies, cells were incubated in 96-well plates at a concentration of 2 × 10 3 cells per well and the plates were incubated for 24 hours at 37 °C in an atmosphere of 5% CO2 prior to drug exposure. Compounds or cisplatin were each dissolved in dimethylsulfoxide to provide stock solutions that were diluted to provide a range of final concentrations. Drug solutions were added to cells (the final DMSO concentrations was less than 0.1% (v/v) in all cases) and incubated for 5 days at 37°C in an atmosphere of 5% CO2. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (20 L, 5 mg mL 1 ) was added to each well and incubated for 4 hours at 37°C in an atmosphere of 5% CO2. All solutions were then removed by pipetting L foxide added to each well in order to dissolve the purple formazan crystals absorbance of each well at 540 nm measured by spectrophotometer. Lanes containing medium only and 100% cells were used as blanks for the spectrophotometer and 100% cell survival respectively. Cell survival was determined as the true absorbance of treated cells divided by the true absorbance of controls and expressed as a percentage. The IC50 values were determined from dose response curves of % survival against drug concentration. Each experiment was repeated three times and a mean value obtained and stated as IC50 M "D.
of complex for 72 hours, media/drug solutions were removed and flasks were washed with PBS (5 mL), adding all collected supernatants to a centrifuge tube. Trypsin (1 mL/flask) was added to each flask and then incubated for 5 minutes until a single cell suspension was obtained. The trypsin was then neutralised with medium (5 mL) and the whole contents of the flask transferred to the same centrifuge tube. The tube was centrifuged at 1000 rcf for 3-5 minutes, the supernatant removed and the pellet re-suspended in PBS (1 mL). The 1 mL suspension was transferred to an Eppendorf tube and centrifuged at 1500 rpm for 5 minutes. The supernatant was removed and the pellet stained with JC-1 in order to stain for loss of mitochondrial membrane potential and apoptosis. This was performed (Chemometec) and cell samples were analysed using an NC3000 flow cytometer (Chemometec). 
Characterisation
